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Highlights:
 Drug penetration through the BBB is a major challenge for treating CNS diseases
 In vitro BBB models are invaluable for evaluating drug transport into the brain
 Benefits and limitations of in vitro BBB models in drug research are discussed
 Contribution of extracellular cell culture matrix is generally ignored
 New outlook on reconstituting BBB models on artificial basement membrane 
platform
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In vitro blood–brain barrier models for drug research: state-of-the-art and new perspectives on 
reconstituting these models on artificial basement membrane platforms
Jayati Banerjee, Yejiao Shi and Helena S. Azevedo*
School of Engineering and Material Science, Institute of Bioengineering, Queen Mary, University of 
London, Mile End Road, London E1 4NS, UK
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Teaser: Engineering of novel synthetic basement membrane matrices for recreating in vitro blood–
brain barrier models with enhanced predictability and paving the way towards customisation in drug 
discovery and development.
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In vitro blood–brain barrier (BBB) models are indispensable screening tools for obtaining early 
information about the brain-penetrating behaviour of promising drug candidates. Until now, in vitro
BBB models have focused on investigating the interplay among cellular components of 
neurovascular units and the effect of fluidic sheer stress in sustaining normal BBB phenotype and 
functions. However, an area that has received less recognition is the role of the noncellular 
basement membrane (BM) in modulating BBB physiology. This review describes the state-of-the-art 
on in vitro BBB models relevant in drug discovery research and highlights their strengths, 
weaknesses and the utility potential of some of these models in testing the permeability of 
nanocarriers as vectors for delivering therapeutics to the brain. Importantly, our review also 
introduces a new concept of engineering artificial BM platforms for reconstituting BBB models in
vitro.
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Introduction
The blood–brain barrier (BBB) is a dynamic interface that separates circulatory blood from the brain 
and exercises strong regulatory control over the influx and efflux of molecules between the brain 
and the bloodstream. Anatomically, the key constituents of the BBB are brain microvascular 
endothelial cells (BMECs), astrocytic end-feet, pericytes and the noncellular basement membranes 
(BMs) that surround and separate these key cellular components from one another. These core 
components, along with neighbouring neurons and microglia, are often singularly appreciated by the 
term neurovascular unit (NVU; Figure 1) [1]. The BBB endothelial cells (ECs) express tight junction (TJ) 
proteins that seal the gap between two adjacent ECs, lack fenestrations and possess few pinocytotic 
vesicles. Thus, the paracellular and transcellular diffusional entry of hydrophilic substances into the 
brain from the bloodstream are greatly restricted. Moreover, the presence of metabolising enzymes 
that can hydrolyse a wide array of exogenous compounds, and a well-defined efflux transport 
system to remove hydrophobic compounds from the cells, further protect the brain from exposure 
to outside toxins, hydrophobic substances and xenobiotics [2]. Owing to this incredible barrier 
protection, most of the central nervous system (CNS)-targeted drugs exhibit poor bioavailability 
because they fail to accumulate in therapeutically relevant concentrations inside the brain 
parenchyma to exert their desired effects. Alternatively, drugs intended to act peripherally should 
preferably be prevented from reaching the brain parenchyma to avoid undesirable toxicity. BBB 
penetration is therefore a crucial aspect that needs to be characterised during different phases of 
the drug discovery and development programme.
Even though in vivo techniques such as brain perfusion are among the most accurate 
methods for assessing the BBB permeability of potential drug candidates, direct in vivo testing is not 
always the best feasible option during the early phases of drug discovery research when it is often 
required to screen combinatorial compound libraries. Further, screening of promising hits for toxicity 
determination is also desirable at an early phase to avoid delays and attrition at later stages [3]. 
Another important aspect that undermines in vivo studies is the differential expression of enzymes, 
transporters and TJ proteins between humans and other species, such as rodents commonly used in 
preclinical testing. Quantitative information on the interspecies variation of protein expression at 
the BBB level can be found in a recent review by Aday and colleagues [4]. Pharmacokinetic 
evaluations (ADME) are typically performed in rodents and the data are then extrapolated to predict 
these characteristics in human models. Yet, functional evidence gathered from positron emission 
tomography images has shown that the human BBB is more permeable to substrates targeting efflux 
transporter P-glycoprotein (P-gp) than that of rodents [5]. Therefore, it makes more sense to carry 
out drug permeability and toxicity studies on human in vitro models rather than in vivo rat models
for predicting drug transport across the human BBB more accurately and reducing the attrition rate 
in the later stages of the drug developmental pipeline. The most simplified approach to reproduce 
the BBB characteristics in vitro is to isolate and culture brain endothelial cells (BECs) in 2D 
monolayers. However, when BMECs or ECs from brain capillaries (BCECs) are isolated from the NVU 
and cultured in vitro they tend to lose their intrinsic barrier properties and consequently it can be 
difficult to correlate in vitro data with in vivo experimental outcomes. The fact that the BBB is a 
complex dynamic interface, and the crosstalk among each component of the NVU is important for 
maintaining the integrity of the endothelial barrier, has led researchers to develop transwell co- and 
tri-culture models to study the influence of astrocytes, pericytes and even neurons in improving the 
tightness of the BBB in vitro [6]. Recent literature has described some innovative models that were 
generated by the differentiation of ECs from hematopoietic and pluripotent stem cell cultures [7,8]. 
Newly reported advanced dynamic and microfluidic models mimicking the flow environment that 
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actually exists in vivo have shown considerable, improved barrier tightness especially with human 
immortalised cell lines when compared with static co-culture models [9,10]. However, these models 
at their current stage of development are technically demanding and unsuitable for high-throughput 
studies [11]. Therefore, a continuous ongoing effort is in progress to develop a model that will retain 
all the major in vivo characteristics of the BBB and yet be simple and cost-effective for routine use in 
high-throughput screens in pharmaceutical research. 
A minimalistic design that can be undertaken in this area is to develop a customised in vitro
model using novel cell culture support materials containing in-built cell signalling epitopes with the 
ability to instruct cells. Such cell culture platforms can mimic the fundamental functions of the 
extracellular BMs and, as such, the cells can respond to the cellular cues provided by the matrix. For 
developing this type of cell culture model, it is important to understand how the BBB BM proteins 
interact with the NVU and how such interactions affect the BBB phenotype and functions. In this 
review, we first briefly discuss the molecular nature of the endothelial barrier and the important 
parameters that one needs to consider in designing cell-based in vitro models of the BBB, followed 
by an overview of the existing in vitro cell-culture models. Next, we explore the impact of the BM, as 
well as cell culture support materials, on the functions of the NVU; finally presenting our ideas from 
a material research point of view about how we can utilise this knowledge to create novel or 
improved versions of pre-existing BBB cell culture models in vitro.
Molecular insights into barrier tightness
The adhesion of BBB ECs is mediated by TJ and adherens junction (AJ) proteins at the 
interendothelial cleft, thus sealing the gap between adjacent ECs and thereby regulating the 
paracellular transport. There are three distinct classes of TJ proteins: (i) the Claudin family 
comprising Claudin-3, -5 and -12; (ii) TJ-associated MARVEL proteins occludin, MarvelD2 and 
MarvelD3; and (iii) immunoglobulin superfamily proteins namely junctional adhesion molecules 
(JAM A, B and C) and EC-selective adhesion molecule (ESAM) [12]. The cytoplasmic C-terminal helical 
domain of Claudins and occludins is designed to interact with peripheral cytoplasmic adapter 
proteins such as zonula occludens (ZO-1, ZO-2, ZO-3), cingulin and junction-associated coiled-coil 
protein (JACOP) [13]. These adapter molecules help to establish a link with the actin cytoskeleton. 
Besides their significant role in structure formation, the peripheral adapter proteins can play an 
active part in cell signalling. Claudin-5 is the major isoform found at the interendothelial junctions 
and a study with Claudin-5-deficient mice has demonstrated size-selective loosening of the BBB 
allowing diffusion of molecules with molecular weight less than 800 Da [14]. This suggests that 
Claudin-5 could have a significant role in maintaining BBB integrity. Additionally, Ohtsuki et al. have 
shown that upregulation of Claudin-5 expression in in vitro rat BEC cultures can enhance paracellular 
tightness [15]. Unlike Claudin-5, the exact role of Claudin-3 at the BBB level is still not fully 
understood. A study has described the degradation of BBB in experimental models of encephalitis or 
human glioblastoma owing to selective loss of Claudin-3 expression [16]. Liebner et al. have reported 
that the expression of Claudin-3 directly correlates with the Wnt/β catenin signalling pathway 
promoting the maturation of the BBB during embryonic development [17]. In in vitro BBB models, 
pericytes in co-culture with BECs can mediate the induction of canonical Wnt signalling events for 
promoting BBB properties [7]. Unlike other members of the Claudin protein family, Claudin-12 lacks 
N-terminal PDZ domains that are responsible for establishing a link with the cytoplasmic adapter 
proteins [18]. In vitro studies have shown that Claudin-12 can mediate vitamin-D-dependent 
paracellular calcium absorption [19]. A study aiming to characterise the localisation of Claudin-12 in 
human hCMEC/D3 cell lines concluded that it is not localised at the TJ of the primary brain 
endothelium, even though it is expressed by primary and transformed brain endothelium [20]. By
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contrast, its expression and localisation at the TJ was prominent during brain development in a 
murine model [16]. It is possible that in vitro localisation of Claudin-12 at the TJ might need specific 
cues from astrocytes or pericytes because, in the aforementioned study conducted with hCMEC/D3 
cells, co-culture conditions were not used because the cells were unresponsive to astrocyte 
conditioning. Furthermore, a literature report has also indicated that the ratio of Claudin-5 to 
Claudin-12 might be significant for TJ establishment; in rats, the expression of Claudin-5 is 751 times 
higher than that of Claudin-12 [15].
The key constituents of the AJ are vascular endothelial cadherin (VE-cadherin) and platelet 
endothelial cell adhesion molecule (PECAM). The linker molecules that link AJ proteins to the actin 
cytoskeleton are the catenins (α, β, γ and p120) [13]. Unlike epithelial cells, where AJ and TJ are 
distinctly separate, in ECs the AJ and TJ are structurally and functionally related. For instance, it has 
been reported that VE-cadherin can upregulate the gene encoding expression of TJ protein Claudin-5 
[21]. From the perspective of in vitro model development with strong barrier characteristics, it is 
essential to prioritise factors that can significantly upregulate the expressions of Claudin-5, occludin, 
ZOs and AJ protein VE-cadherin. Antibodies to Claudin-5, occludin and ZO-1 are commonly used as 
qualitative markers to identify the expression of these proteins in in vitro monolayer cultures of BBB 
ECs. 
Quantitative and qualitative parameters defining BBB
A perfect cell culture model would ideally mirror BBB phenotypes and functions that exist in vivo, 
however such an ideal situation is difficult to realise especially with systems as complex as the BBB. 
In principle, an ideal BBB model for drug testing needs to incorporate the following features: 
expression and localisation of endothelial TJ and AJ proteins, selective permeability to molecules 
based on their oil–water partition coefficient and molecular weight, selective and asymmetric 
permeability to physiologically relevant ions, low fluid phase activity, expression of relevant nutrient 
and efflux transporters, receptors and drug-metabolising enzymes, easy culture conditions and low 
cost [22]. In in vitro cell models, the barrier tightness of the BEC monolayers is quantitatively 
assessed by measuring transendothelial electrical resistance (TEER), which measures the resistance 
towards diffusion of Na+ and Cl− ions. This value provides a rough estimate of barrier tightness 
because actual TEER is unmeasurable for brain capillaries in vivo. In adult rat brain parenchymal 
vessels, an approximate electrical resistance as high as 8000 Ω·cm2 has been estimated on the basis 
of combined permeability measurements of three radioisotopic ions (sodium, potassium and 
chloride) and the TEER in brain arterial vessels is around 1200 Ω·cm2 [23,24]. Based on these data, it 
is safe to estimate a TEER of more than 1000 Ω·cm2 in the mammalian BBB, including that of human. 
Even though a minimum TEER range from 150 to 200 Ω·cm2 is sufficient to carry out drug 
permeability studies [25], higher TEER is more likely to reflect a strong TJ with enhanced resistance 
to paracellular diffusion; therefore, achieving superior TEER is the fundamental criteria for 
evaluating the quality of BBB models. However, it is prudent to exercise caution when comparing the 
effectiveness of different BBB models solely on the basis of TEER because TEER depends largely on 
the experimental procedures adopted [26]. For example, TEER value depends on the measuring 
equipment – TEER measured by two different types of instruments [traditional voltohmmeter type 
chopstick electrodes (EVOM) vs modern cellZscope® system] would be different, and therefore is not 
recommended for comparison. Again, measurement using the chopstick method might not 
accurately reflect the true value of TEER because measurement varies with the position and angle of 
the electrodes. Finally, in addition to TJ protein composition, size of the compound of interest can 
also affect TEER. In transwell cultures, ECs are seeded on a polyethylene or polycarbonate filter 
insert coated with cell-support materials. The filter inserts divide the transwell chamber into two 
distinct compartments – the apical or upper compartment representing the blood side and the lower 
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or basolateral compartment representing the brain parenchyma. The TEER value of the confluent 
endothelial monolayer is obtained by inserting two electrodes, one on each compartment, 
separated by the semipermeable filter insert (Figure 2). If the TEER for controls, as shown in Figure
2bi and 2ci, is not measured and subtracted properly then it can mislead the interpretation of results 
regarding the actual contribution of the ECs towards TEER for that particular model.
Interestingly, it has been found that TEER varies depending on the pore size, choice of filter 
material and seeding density. Polyethylene terepthalate (PET) filters can impart better barrier 
properties than polycarbonate filters, whereas membrane pore size of 0.4 µm has shown the highest 
TEER value in comparison with pore sizes of 1, 3 and 8 µm in murine in vitro BBB models [27]. A 
paper published very recently by Vandenhaute et al. helps in explaining this lowering of TEER with 
increasing filter pore size [28]. In their quest to optimise an in vitro BBB model that would allow 
migration of metastatic cancer cells across the seeded endothelial monolayer, Vandenhaute and 
colleagues observed a second layer of ECs on the lower opposite side of the filter with a pore size of 
3 µm. They reasoned that ECs from the seeded monolayer at the top of the filter could cross the 
filter insert because of the larger pore size and colonise on the bottom face of the filter. Because of 
this double layer formation, the model deviates from the actual monolayer structure that persists in 
vivo. The polarity of the barrier system might even be destroyed because of the presence of this 
second layer. Consequently, the authors reported a decrease in permeability coefficient, and 
possibly this led to the decrease in TEER observed. A minimal optimal seeding density of 4 × 105
cells·cm-2 has also been found to be crucial for increasing TEER [29].
In addition to electrical resistance, the paracellular transport capacity can be determined by 
measuring permeability of tracer compounds, such as sodium fluorescein (NaF), lucifer yellow (LY), 
fluorescein isothiocyanate (FITC)-labelled dextrans, FITC-inulin, FITC-bovine serum albumin, sucrose
and mannitol. The marker compounds cannot be potential ligands for membrane receptors and 
efflux transporters or a substrate for BBB-metabolising enzymes. The endothelial permeability 
coefficient (Pe) of sucrose in in vivo rat models can be as low as 0.03 × 10-6 cm·s-1 [30]. Usually TEER 
and Pe have direct correlation for small hydrophilic molecules, however paracellular permeability is 
largely dependent on the molecular weight and charge of the molecule and as such cannot be 
extrapolated for just any solute. Therefore, to get a more realistic assessment of barrier permeability, 
it is advisable to measure permeability of tracers with different molecular weights [e.g., 0.18 kDa 
mannitol, 0.342 kDa sucrose, 0.45 kDa LY, 3kDa Texas Red (TXR)-dextran, 20 kDa 
tetramethylrhodamine (TMR)-dextran and 70 kDa FITC dextran] [31]. Moreover, the correlation 
between TEER and permeability measurement is also influenced by different experimental protocols, 
hence TEER and paracellular permeability data should be considered in analysing the quality of the 
model in terms of barrier permeability [26].
The brain EC membranes express a broad range of ATP-binding cassette (ABC) transporters 
that prevent many hydrophobic drugs from entering the brain and also excrete harmful metabolic 
waste out of the brain. In humans, the most well characterised ABC transporters, the expression of 
which in BBB models is key in evaluating drug transport mechanisms, are P-gp/ABCB1, multi-drug 
resistance protein (e.g., MRP-1, MRP-5) and breast cancer resistance protein (ABCG2). The function 
of these transporters can be quantitatively assessed by determining the efflux ratio, which measures 
the permeability of substances across the transwell semipermeable membrane from apical to 
basolateral as well as from basolateral to apical compartments [6]. Selective inhibitors can block 
specific transporters. Therefore, by using these inhibitors, one can categorically identify the 
transporter to which the given drug molecule binds. P-gp, in particular, can act on a diverse range of 
drug substrates with very different pharmacophores. The review by Giacomini et al. contains details 
about important efflux transporters that are particularly relevant in clinical pharmacology and drug 
discovery [32].
Page 8 of 41
Ac
ce
pte
d M
an
us
cri
pt
Remarkably, contrary to its barrier functions, the BBB has precise mechanisms for supplying 
nutrients into the brain [33]. For example, small ions and water can pass through by the opening of 
ion channels and small lipophilic molecules (e.g., ethanol, nicotine, caffeine, barbiturates) are 
soluble in the hydrophobic lipid membranes of ECs and can enter into the brain by passive diffusion. 
There are specialised carrier-mediated transporters for transporting polar nutrients, such as glucose 
(GLUT-1 or SLC2A1), large neutral amino acids (LAT-1) and organic cations and anions (OATP1A2). 
Some of these transporters also exhibit overlapping substrate specificities. Large proteins (e.g., 
albumin, histone), hormones (e.g., insulin) and immune traffickers[s1] (e.g., transferrin, IgG) are 
internalised into the brain parenchyma by receptor- or adsorption-mediated transcytosis. It is to be 
noted that drugs can be delivered into the brain by utilising one of these transport mechanisms. The 
in vitro model aimed for drug delivery studies must therefore express suitable receptors on the 
surface of the ECs.
In vitro models of the BBB
Monoculture models
In in vitro monoculture transwell models, a uniform layer of BECs is seeded on a semipermeable 
membrane filter support (Figure 3a) and, depending on the pore size of the filter, cell trafficking 
experiments as well as drug transport studies can be performed. The BECs cultured can be primary 
or immortalised cell lines and the model can be constructed using BECs from any animal species 
(human, mouse, rats, bovine, porcine and monkey) [34]. Monoculture of ECs is the most basic of the 
BBB models and because of its simplicity it is highly suited for high-throughput screening. However, 
the major drawback with monolayer cultures is the absence of the influence of other cellular 
components of the NVU and inadequate barrier properties. Therefore, the most popular in vitro
models of the BBB are co-culture models that consider the interactions between ECs and the 
surrounding brain microenvironment.
Co-culture models
In 1987, Janzer and Raff demonstrated that astrocytes could induce BBB-like TJ characteristics in 
chick ECs of peripheral origin, and in the same year Tao-Cheng et al. reported that astrocytes re-
enhanced TJ of brain endothelium [35,36]. Ever since the findings from these two independent 
studies were published, astrocytes or astrocyte-conditioned medium have been extensively used in 
co-culture models with ECs. A detailed list of endothelial–glial co-culture models including TEERs and 
effect of permeability on tracer substances are presented in reviews by Deli et al. and, more recently,
by Wolff et al. [37,38]. In most of these models, especially those using primary rat astrocytes, the 
paracellular barrier properties were significantly improved. The nature of glial cells in endothelial–
glial co-culture models can be primary cells of the rat, mice and human/human-fetal or cell lines 
such as rat C6 glioma, rat CTX-TNA2 and rat SV40. Moderately high TEER (~400–500 Ωcm2) and a 
decrease in permeability of sucrose were observed in bovine ECs co-cultured with rat astrocytes 
[39,40]. A major advantage of using bovine or porcine ECs over rodents is that a large volume 
fraction of the brain capillaries can be isolated because of the large size of the brain. Smith et al.
reported a TEER of 900 Ωcm2 on a co-culture model of porcine ECs with rat C6 astroglioma [41]. 
Recently, maximum TEER in the range 1700–2200 Ωcm2 along with extremely low permeability of LY 
(Pe = 0.46 × 10-7 cm·s-1) was documented by Cantrill et al. using co-cultures of porcine BCECs with a 
new immortalised astrocytic cell line CTX-TNA2 from rat [42]. However, it is to be noted that this 
high TEER of ~2000 Ωcm2 was obtained when porcine BCECs were pre-treated with puromycin; the 
cells untreated with puromycin showed a dramatic decrease in average TEER (182 Ωcm2) under 
similar co-culture conditions. Puromycin has been employed in BBB studies to purify primary BECs, 
which are often contaminated with astrocytes, pericytes or smooth muscle cells. The idea behind 
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this operational step is that, because BECs express higher concentrations of P-gp than contaminating 
astrocytes and pericytes, ECs would resist puromycin treatment by effluxing puromycin out of the
cells, whereas the contaminating cells would respond to this treatment and therefore can be easily 
separated. Moreover, because of the higher P-gp expression, high toxic concentrations of puromycin 
can be tolerated by the cells. Previous literature evidence has demonstrated a significant rise in TEER 
for monolayer culture of primary rat BECs purified with puromycin. Also in co-culture models with 
astrocytes, in the presence of cAMP, puromycin-treated rat brain endothelial monolayer 
demonstrated reduced permeability to NaF (0.75 × 10-6 cm·s-1) and an increased TEER of 500 Ω·cm2
[43]. In the aforementioned case, the authors argued that using contaminated primary ECs could
affect the barrier integrity of cell monolayers resulting in low TEER (182 Ω·cm2) [42] and their 
argument aligns well with previous literature evidence. In addition to puromycin, the astrocytic cell 
line CTX-TNA2 was also a contributing factor towards tight barrier formation because puromycin 
pre-treated BEC monoculture showed similar TEER to that of untreated cells in co-culture. 
Immunocytochemical analysis revealed the expression and localisation of ZO-1 and occludin at the 
cellular periphery. In co-culture systems, glial cells and also pericytes can be cultured either at the 
bottom of the well (noncontact configuration, Figure 3bi,biii) or can be seeded at the opposite side 
of the filter insert in which case they are supposed to interact closely with ECs (contact mode, Figure 
3bii,biv). In a comparative study using an in vitro co-culture model of primary porcine BCECs with rat
glial cells, Malina et al. demonstrated that contact orientation produced significantly higher TEER 
(~1112 ±43 Ωcm2) and low paracellular permeability of sucrose (~0.19 × 10-6 cm·s-1) [44]. The model 
used 10 µm polycarbonate filters with 0.4 µm pore-size. Previous literature evidence demonstrated 
that pore diameter of 0.4 µm would enable astrocytic foot-processes to pass through the pores and 
establish physical contact with the ECs seeded on the filter support, whereas the passage of 
astrocytic cell body to the side of the seeded EC monolayer would be restricted [45]. Moreover, the 
thickness of 10 µm was just the right distance for astrocyte-released soluble factors, which are 
relatively short-lived, to reach the seeded endothelial monolayer because they might become 
inactive while traversing a longer distance of 100 µm from the bottom of the well in a noncontact
co-culture system. By contrast, Shayan et al. demonstrated, with clear confocal images on a murine 
back-to-back (contact) co-culture model with rat astrocytes, that on a 0.4 µm diameter filter
astrocyte foot-processes actually blocked the pores by passing halfway through them [46]. This not 
only prevented physical contact of foot processes with the endothelial monolayers but also might 
prevent the astrocyte-derived soluble factors from reaching the seeded ECs on the opposite side of 
the filter. Consequently, the authors found no significant difference with regard to barrier tightness 
and paracellular permeability between endothelial monolayer cultures and contact co-culture 
configuration. When they tested permeability for a combination of hydrophobic and hydrophilic 
drugs by culturing astrocytes in a non-back-to-back fashion, the TEER obtained was not significantly 
high but was comparable to values reported in mouse endothelial co-culture models and,
importantly, the model produced an excellent agreement with in vivo drug permeability data 
(correlation coefficient = 0.98) [46]. Concerning the significance of these studies, a key point worth 
discussing is that astrocytes and ECs are separated by the BM and they are not in contact in vivo. 
Therefore, culturing glial cells at the bottom of the filter to establish physical contact with ECs might
not necessarily have a profound impact in influencing EC integrity. Moreover, TEER and permeability 
values should also be reported with astrocytes cultured at the bottom face of the filter without ECs 
seeded at the top because the presence of two layers of cells at the bottom and the top could alter 
model characteristics. Astrocytes can even metabolise certain compounds (e.g., propranolol) and 
this can introduce artefacts in permeability measurements. However, the clogging of the filters by 
astrocytic end-feet can serve as a physical barrier towards diffusion of soluble factors into the side of 
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the cultured endothelial monolayer and thus the contribution of these factors in influencing BBB 
properties would not be perceived.
In most of these co-culture models, astrocytes seem to modulate the TJ protein expression
at the interendothelial cleft thus influencing paracellular permeability; additionally, the efflux 
transporter expression (ABCB1 and ABCG2) has also been found to be upregulated by astrocytes. 
Astrocytes also secrete a variety of soluble factors such as glial-derived neurotrophic factor (GDNF), 
basic fibroblast growth factor (bFGF), interleukin-6 (IL-6), transforming growth factor-β (TGF-β), 
angiopoietin-1 (Ang-1) and Sonic hedgehog (Shh) [1,47,48]. These factors are strongly believed to 
influence the maturation and maintenance of the BBB phenotype at a steady-state level [49,50]. 
Consequently, brain EC monolayers have been cultured in the presence of astrocyte-conditioned 
media to induce the BBB phenotype in vitro [51]. Although these models were unable to display 
significantly high TEERs, they are usually simple to maintain, culture and mostly compatible with 
high-throughput screens. 
Even though astrocytes have garnered tremendous attention in in vitro BBB modelling, 
studies related to the functional influence of pericytes in the development of fundamental BBB 
characteristics are rare, with more reports emerging in recent years despite the fact that pericytes 
are the closest neighbour of the BMECs and they might be the first cell type of the NVU that the 
developing BMECs come in contact with during embryogenesis when astrocytes are not even 
differentiated [52,53]. One plausible reason for this lack of study is the absence of brain-specific 
pericyte markers. However, recent literature suggested platelet-derived growth factor receptor-β 
(PDGFR-β) could act as a specific marker for unambiguously identifying brain pericytes because mice 
devoid of PDGFR-β or its binding ligand completely lack brain pericytes [54]. In general, in cell culture 
models, PDGFR-β is used along with multiple pericyte markers alpha-smooth muscle actin, neuron-
glial 2 (NG2) and vimentin for identifying pericytes [55]. Pericytes produce TGF-β, which induced 
barrier tightness and upregulated P-gp activity in a mouse brain endothelial cell line (MBEC4) co-
cultured with rat pericytes [56]. In bovine BCECs, pericytes increased mRNA expression levels 
corresponding to MRP-6 efflux protein [57]. Nakagawa et al. have explored in detail the effect of 
pericytes and astrocytes by developing tri-culture syngenic in vitro models with rat BCECs, astrocytes 
and pericytes. Out of seven different combinations, involving monoculture, co-culture and tri-culture 
arrangements, the model that closely resembled the in vivo anatomical organisation with pericytes 
cultured opposite to the seeded endothelial monolayer (contact arrangement, Figure 3ci) and 
astrocytes at the bottom of the well (noncontact orientation) produced the highest TEER (400 Ωcm2) 
and low paracellular permeability of fluorescein marker (Pe = 3 × 10-6 cm·s-1) [58]. In a later study, 
they characterised this model thoroughly by highlighting the expressions of junction proteins, GLUT-
1, efflux transporter P-gp and MRP-1, in addition to obtaining a good in vivo correlation with regard 
to drug permeability studies [59]. In the in vivo situation, pericytes establish physical interaction with 
ECs through peg and socket contacts whereas the space between peg and socket junction contains
growth factors (GFs) or signalling molecules that mediate crosstalk between the two cell types [60]. 
To investigate the effect of EC–pericyte physical interactions on BBB physiology, Vandenhaute et al.
devised a tri-culture model containing bovine pericytes and BCECs cultured together on the 
semipermeable membrane for facilitating close interaction, whereas rat astrocytes were cultured in 
the well (Figure 3ciii). Captured electron microscopic images revealed very close contact between 
the endothelial monolayer and pericytes and the ECs exhibited low paracellular permeability and 
expressed efflux transport protein P-gp. However, when this model was compared with the 
noncontact co-culture setup in which the ECs were seeded on the filter with pericytes and astrocytes
at the bottom of the well (Figure 3civ), the paracellular permeability was lower than the close 
contact model [55]. 
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Most of these tri-culture models utilised bovine or porcine brain BCECs co-cultured with rat 
astrocytes and pericytes in a calf-serum medium. Therefore, one might not get accurate information 
when the results from these models are extrapolated to predict the behaviour of drug transport in 
humans. This prompted researchers to generate all-human mono-, co- and tri-culture models using 
an immortalised human (hCMEC/D3) cell line, human astrocytic cell lines (CC-2565 and SC-1810) and 
human brain pericytes [61]. This model [s2]closely resembled Nakagawa’s tri-cultivation model 
applied on an all-human set-up [58]. The cells were allowed to grow in the cell culture medium 
containing human serum. Surprisingly, the tri-culture model involving all three cell lines with 
pericytes seeded at the bottom of the filter, allowing close contact with ECs, proved to be inferior to 
the co-culture models using either astrocytes or pericytes. Moreover, the astrocyte contact co-
culture conditions produced higher TEER than pericyte co-culture even though the highest TEER 
value measured was less than 100 Ωcm2 [54]. Therefore, it can be concluded from thei  findings that 
the barrier tightness in a human in vitro BBB model is effectively lower than that of other species, 
and the inclusion of pericytes does not enhance the formation of TJs in contrary to what Nakagawa 
and co-workers have observed in their models. However, throughout this study, apart from TEER, no 
other measurements such as permeability of tracers or analysis of the expression of TJ proteins and 
transporters were conducted. Thus, no other significant parameters can be taken into guidance to 
support any major conclusion derived from this study.
Neurons maintain close association with astrocytes and hence can indirectly regulate BBB 
permeability by modulating the properties of ECs through astrocytes. Hence, it is more sensible to 
setup tri-culture models of neurons with astrocytes to analyse the synergistic influence of neurons 
and/or [s3]glia on EC permeability. A syngenic tri-cultivation model developed from rat primary 
BMECs, astrocytes and neurons recorded an increase in TEER by 35.9% (actual value = 268 Ωcm2) 
when compared with endothelial monoculture and co-culture models involving either astrocytes or 
neurons with BMECs. Notably, the model also demonstrated increased expression of P-gp 
transporter and ZO-1, as well as low permeability to NaF [62]. 
A significant number of the co-culture models described above have produced suboptimal 
TEER values, which is substantially lower than what is found in vivo, high paracellular permeability, 
lack of expression of important transporters, enzymes and inconclusive data arising from lack of 
reproducibility under similar experimental paradigms. It is also noteworthy that, even though many 
details of the astrocytic influence in modulating EC behaviour are unknown, as a general trend
astrocytes have performed consistently better in improving TEERs than pericytes. It is well accepted 
that glial cells can induce the expression of TJ proteins, efflux transporters and enzymes in BECs and 
thereby aid in barrier tightness [1]. However, it is too early to undermine the role of pericytes 
because elaborate studies need to be conducted to unravel the exact contribution of astrocytes and 
pericytes in forming a restrictive barrier. In this regard, it can be argued that the mechanism of 
pericyte differentiation must be taken into account when establishing models containing pericytes. 
For example, information gathered from the literature suggested that pericytes differentiated with 
TGF-β could negatively affect TEER, whereas pericytes differentiated with bFGF were found to 
increase TEER [63].
Human cell-based models
Immortalised cell lines. Human cell-based BBB models are important for translation of therapies to 
humans, because there are differences among transporter genotypes between human and other 
species. To investigate delivery of drugs to the human brain, it would be ideal to use primary human 
BECs (hBECs) because it would eliminate interspecies variations; but, as a result of stringent 
regulations and restrictions, it is difficult to experiment with hBECs. Moreover, the source of 
obtaining human primary cells is from cryopreserved tissues that had been removed surgically and 
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hence they might not be regarded as healthy cells. Because access to healthy human BBB tissue is 
restricted on ethical grounds, to date only a few immortalised cell lines have been developed to 
generate human BBB models in vitro. The HCMEC/D3 cell line was first reported by Weksler et al. in 
2005, and since then more than 100 publications have reported using this cell line for understanding 
the mechanisms associated with CNS pathology, immune response and drug transport studies 
[64,65]. As a result, the HCMEC/D3 cell line is extensively characterised compared with all other 
human immortalised cell lines. This cell line expresses important endothelial markers including CD34, 
CD31, CD40, CD105, CD144 and the von Willebrand factor; by comparison, another human cell line 
(HBEC-5i) does not show positive staining for the CD31 marker [65,66]. Moreover, hCMEC/D3
monolayers express important TJ proteins and are reported to form a tight and effective barrier for 
compounds with high molecular weight, as demonstrated by lower permeability values for 4 kDa 
dextran (5–13 × 10-6 cm·s-1) and 70 kDa dextran (0.2–0.3 × 10-6 cm·s-1). In fact, for compounds having 
MW ≥4000 kDa, paracellular permeability closely resembles the profiles reported for well-
characterised bovine and porcine models. Additionally, expression of 44 SLC transporters (GLUT-1, 
LAT-1 and MCT family transporters), receptors such as insulin and transferrin and 23 efflux 
transporters of the ABC family, which include P-gp, MRP-4 and BCRP, has endowed this cell line 
particularly amenable for drug uptake and active transport experiments [26,67]. However, a major 
area of concern that can limit its potential for routine use is the low TEER range (30–50 Ω·cm2) and 
enhanced permeability of paracellular markers with low molecular weight – sucrose, mannitol, NaF 
and LY – average range (20–90 × 10-6 cm·s-1). In this regard, it has been observed that treatment with 
the anti-inflammatory steroid hydrocortisone, or addition of lithium chloride (LiCl) which can induce 
Wnt/β catenin canonical signalling, can increase TEER [68]. This signifies that modulation of TJ 
protein expression associated with barrier tightening is necessary to improve TEER. This observation 
is also supported by a study in which detailed transcriptional profiling at the mRNA expression level 
was performed on HCMEC/D3 cells and then this profiling was compared with published data 
available for freshly prepared mouse BECs [69]. The TJ proteins, specifically Claudin-5, occludin, as 
well as some members of SLC and ABC family transporters, were found to be expressed in low levels 
compared with mouse BECs. Probably, addition of hydrocortisone or Wnt activator LiCl increased the 
expression level of Claudin-5 or occludin, thereby enhancing TEER. Pollar et al. have reported a 
decrease in sucrose permeability 39 times by substituting fetal bovine serum (FBS) with human 
serum in the cell culture medium [70]. The all-human tri-cultivation model used human serum, but 
sucrose permeability was not determined to evaluate its effect. Another human cell line BB19 was 
developed as early as in 1996, but its use is limited because of high sucrose permeability [71,72]. No 
permeability data were reported for human cell lines NIKM-6, HCEC, HBEC-5i and HBMEC-3 
[65,66,73,74]. The HBMEC-3 cells also lack any phenotypic characterisation. The TY08 cell line 
showed lower levels of P-gp expression and permeability coefficient 1.23 × 10-3 cm·s-1 for inulin 
tracer [75,76]. The recently developed HBMEC/ciβ cell line showed initial promising data, in terms of 
endothelial expression markers, proliferation capacity and expression of TJ proteins, P-gp and BCRP;
but an average value for TEER was not reported, although it was mentioned that the TEER was poor, 
indicating low barrier strength. The paracellular permeability of sucrose was also several-fold higher 
than that in vivo [76]. The TY10 cell line immortalised by transduction of temperature-sensitive SV40 
large-T antigen showed initial promise in their ability to express Claudin-5, occludin and ZO-1. At 
33°C these cells were able to retain their morphology up to 50 passages, but when the temperature 
was shifted to 37°C loss of SV40 large-T antigen occurred [77]. To optimise a cell line for high- to 
medium-throughput permeability screening, a comparative study using four different human 
immortalised cell lines (hCMEC/D3, hBMEC, TY10 and BB19) was performed on a 24 well plate 
format. The best optimised model in terms of highest TEER (40 Ωcm2) and lowest paracellular 
permeability of LY (5.39 ±0.364 × 10-6 cms-1) was obtained with hCMEC cell lines in monolayer 
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cultures on a transparent PET membrane of 3 µm pore size. However, hCMEC/D3 and hBMEC cell 
lines expressed AJ proteins, as well as ZO-1, whereas TY10 along with hCMEC/D3 were able to 
express Claudin-5, which was also detected in low amounts in hBMEC [78]. The TEER for monolayer 
culture was measured using cellZscope®, hence it cannot be compared with TEERs reported 
previously for monolayer culture of these cell lines using EVOM. The measurements in this study 
were done using several culture inserts, bought from different suppliers and of varying filter sizes, 
different cell seeding density and in the presence of several growth media to optimise the best 
possible conditions in terms of achieving highest TEER and lowest parcellular diffusion. Surprisingly, 
no change in TEER was observed upon replacing FBS with human serum. This could be caused by
variation in the FBS composition attributed to different commercial sources. Interestingly, tri-
cultivation of these cell lines in the presence of astrocytes (SVG-A cell line) and human pericytes 
(HBPCT cell line) showed no improvement in TEER, an observation that is consistent with previous 
study results [39,40]. It is to be noted here that TEER for the triple culture model was measured with 
EVOM because the cellZscope®, owing to its basic design, does not support the format in which cells 
are seeded at the bottom [78].
Stem cells. Human immortalised cell lines can act as substitutes for primary cells but, as discussed 
above, they do suffer from serious limitations, the primary drawback being their inability to form a 
tight barrier under optimum culture conditions as indicated by inferior TEERs relative to an in vivo
environment [65,78]. Under such a scenario, human stem cells are the best resources for generating 
human brain-like endothelial cells (hBLECs) in large scales. In stem cell culture models pioneered by 
Shusta and co-workers, hBLECs were obtained by the differentiation of human pluripotent stem cells 
(hPSCs) [8,79]. Under contact co-culture conditions with neural cells, the BLECs acquired strong 
paracellular barrier functions (TEER = 1450 ±140 Ω·cm2) with expression of well-defined nutrient and 
efflux transport systems [8]. In a further complex mixed culture adaptation of this model, the hBLECs 
were derived from retinoic-acid-treated hPSCs and were allowed to grow in the presence of neural 
progenitor cells that differentiated into astrocytes, pericytes and neurons. Retinoic acid was used to 
improve the BBB phenotype of the ECs by increasing occludin and VE-cadherin expression. The peak 
TEER recorded for this model after 25 h of culture was extremely high (5000 Ω·cm2) [79]. To date, 
[s4]this is the highest TEER recorded by an in vitro BBB model. Even though these innovative stem cell 
culture BBB models displayed impressive barrier characteristics, and can meet the demands for 
large-scale production of in vitro BBB models, the models suffer from some serious drawbacks: the 
differentiation process involving the stem cells was complex and the peak TEER started to decrease 
after 50 h of culture. The TEER was also dependant on the initial source of hPSCs. Moreover, the 
phenotypic characteristi s of the cellular components were not adequately described and the in 
vitro permeability data were compared with rat in vivo uptake and not human. The other two stem 
cell models used human cord hematopoietic stem cells to derive hBLECs. One study demonstrated 
upregulation of occludin, GLUT-1 and P-gp in hBLECs derived from human endothelial progenitor 
cells and co-cultured with astrocytes for 15 days. However, the TEER measured for this model was 
very low (60 Ω·cm2) and the optimum paracellular permeability was sustained for only 4 days. 
Additionally, in vivo correlation comparison profile related to the permeability measurement was 
not described [80]. The other study is comparatively more relevant, because it is the first study of its 
kind to obtain a correlation coefficient (0.89) with in vivo human permeability data [7]. The TEER 
reported for this model was 175 Ω·cm2 and the authors demonstrated that the induction of barrier 
properties was at least in part mediated by the clues provided by the canonical Wnt signalling 
pathway from pericytes. This is a significant finding related to understanding the underlying 
mechanisms of regulating BBB phenotype and functions by pericytes. Prior studies have associated 
angiopoietin-1 and TGF-β secreted from pericytes in inducing TJ and regulating normal functions of 
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the BBB [56,81]. But this is the first time the Wnt signalling pathway has been associated with 
pericytes in developing BBB properties in vitro. Also, this model is highly reproducible because it was 
reproduced in several laboratories using stem cells from different donors. The model could retain 
the optimal paracellular permeability value of LY for 20 days and thus can be considered stable for at 
least 20 days. In principle, this model presents many attributes of a promising human in vitro BBB 
model for standard use in drug discovery programs – stability, scalability, reproducibility and a good 
correlation with human in vivo permeability. However, the TEER for this model is still relatively low 
in comparison with the in vivo situation, and the permeability coefficient has been reported for only 
nine compounds, which by no means is exhaustive enough to conclude the true predictive potential 
of this model for testing permeability of a new generation of CNS therapeutics. 
Dynamic models
The BECs use a hollow cylindrical geometry and operate in a laminar flow regime. The BECs respond 
to the effect of shear stress by redistribution and flattening of cell fibres (structural remodelling) or 
in other words shear stress can regulate the functions and morphology of the BBB [82]. The 3D 
dynamic BBB models have definitive advantages over 2D models because they allow researchers to 
study the effects of confinement, geometry and flow conditions on cell behaviour. Confinement is 
important to recreate the constriction of the flowing blood cells in the capillaries by the vessel walls. 
It is impossible to reproduce the effect of confinement in 2D models. The in vivo blood flow confined 
to a hollow cylindrical capillary was mimicked in vitro by culturing BECs on the inner surface of 
cylindrical hollow fibres. The outer surface of the hollow fibres was coated with poly-D-lysine (PDL) 
which supports co-culture with astrocytes. A bundle of these hollow fibres was placed inside a 
sealed chamber supplied with electrodes for continuous TEER monitoring (Figure 4). The cell culture 
medium circulating inside the hollow tubes could generate a physiologically relevant shear stress of 
~5 dyne·cm-2. The use of these 3D artificial hollow fibres representing capillary-like geometry 
provided larger surface area for cell–cell communication and improved shear environment. This kind 
of model was initially developed and studied extensively by Cucullo et al. [83]. By applying flow 
conditions on primary human BECs co-cultured with astrocytes, a TEER of 1000 Ω·cm2 was recorded; 
sucrose permeability was below 2 × 10-7 cm·s-1 [84]. Under similar conditions, human immortalised 
hCMEC/D3 cell lines also recorded a similar TEER, a substantial improvement compared with static
models, but the astrocytes co-cultured with hCMEC/D3 seemed to have no effect in influencing TEER
[85]. Despite obtaining high TEERs with human cells, the dynamic model has many specific 
disadvantages as outlined by Naik and Cucullo: substantial amounts of cells are required to fill the 
large capillary volumes, real-time monitoring of cell behaviour in the inner luminal surface is 
impossible, high-handed technical skills are needed to set up the model and, compared with 
conventional static transwell systems, this apparatus is incompatible with high-throughput 
pharmaceutical screening [11].
The microfluidic device uses small fluid volumes and therefore requires fewer cells. Also, the ECs can 
be exposed to a physiologically relevant sheer stress benefitting from a well-defined laminar flow 
offered by the microfluidics. This model system was found to increase TEERs for human hCMEC/D3 
cell lines (from 40 Ω·cm2 without sheer to 120 Ω·cm2) and seemed to upregulate ZO-1 expression in 
the endothelial membranes [9]. Another benefit of microfluidic models is that visualisation of cells is 
made possible by the transparent nature of the materials used. However, in spite of promising 
benefits and outcome, the model is unable to reproduce the exact geometry of the in vivo
microvascular phenotype and the TEERs reported were not extraordinary (250–300 Ω·cm2) 
compared with other forms of existing in vitro BBB models [9,86,87]. 
Assessing nanocarrier permeability using in vitro BBB models
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Because lipophilic drugs can cross the BBB more easily through passive diffusion, one strategy would 
be to modify hydrophilic drugs by attaching chemical moieties that would make the overall molecule 
nonpolar. The downside of this modification is nonselective delivery and unwanted accumulation of 
drug in peripheral organs. Other strategies that can be undertaken include inducing temporary or 
transient disruptions of the BBB resulting in increased permeability. The stimuli for this type of 
disruption could include chemical agents that can reversibly modulate TJ and AJ proteins and 
increase temporarily paracellular permeability aiding in the diffusion of the drug [88]. 
Stimuli of the physical origin such as application of ultrasound can also cause temporary 
reversible disruptions of the junction proteins [89]. However, this temporary noninvasive disruption 
carries a significant risk and the extent of the disruption needs to be strictly controlled. The most 
useful strategy in this regard is a targeted delivery approach in which the drug is formulated in a 
suitable vector that can cross the BBB by receptor- or absorption-mediated transcytosis [90,91]. 
Examples of such nanocarriers include liposomes, micelles, polymeric nanoparticles, dendrimers, 
quantum dots, iron oxide or metal-based nanoparticles and nanoparticles composed of solid lipids 
[92]. Although simple cost-effective models are desirable for medium- to high-throughput screening, 
more complex co-culture models have been more popular for evaluating nanoparticle delivery. 
Some examples of nanoformulations, and the commonly employed in vitro BBB models used for 
testing their penetration ability, are illustrated in Table 1. Among different cell types, the popular 
choice is primary BECs from rat, mouse, bovine, porcine and human, whereas human and rat 
immortalised cell lines HCMEC/D3 and b.End3, respectively, have been used in testing many of these 
nanoformulations with or without cargoes loaded. Surprisingly, immortalised cell lines from 
noncerebral origin such as Madin–Darby canine kidney (MDCK) and human colorectal 
adenocarcinoma (Caco-2) have also been used for testing drug permeability because these cell lines 
form tight monolayers under suitable culture conditions [93,94]. However, the fundamental 
disadvantage of using these cells of epithelial origin is the display of completely different phenotypic 
morphology in culture – narrow tall [s5]verses usual long spindle shapes for BECs. The primary 
expectation from using in vitro models is to identify an optimal formulation that subsequently would 
demonstrate equivalent in vivo efficacy. In an excellent review by McCarthy and colleagues, a 
comparison with in vivo data for some of these formulations tested using in vitro models is provided, 
and the results show that in some specific cases in vitro experiments were successful in identifying 
formulations that would demonstrate enhanced in vivo efficacy [95]. This seems encouraging, but 
translation of these results from animal models to humans still remains a major hurdle to overcome 
and the root of this challenge lies in the development of human in vitro models adequately 
reproducing important human BBB phenotype and functions. Although some of these therapeutics 
encapsulated in liposomes have made it to Phase I and Phase II clinical trials 
(https://clinicaltrials.gov), as of yet no therapeutics in nanoformulations are available on the market 
to treat CNS-related disorders [95].
BBB basement membrane
The BM is the noncellular counterpart of the NVU and at the BBB level there are two distinct BMs in 
close contact with each other and apparently they cannot be differentiated under a light microscope. 
The endothelial BM separates ECs and pericytes, whereas the parenchymal BM (also known as glia 
limitans/astrocyte BM) separates astrocytes from ECs. The two BMs have different compositions 
based on laminin isoforms. Laminins are glycoproteins containing three subunits (α, β and γ; Figure 
5b) and, depending on the combination of these subunits in different stoichiometric ratios, 
formation of several isoforms is possible. The laminin isoforms 411 (α4β1γ1) and 511 (α5β1γ1) are 
secreted by the ECs and they form the major constituents of endothelial BM, whereas parenchyma 
BM is primarily composed of laminin 111 (α1β1γ1) and 211 (α2β1γ1) isoforms, which are secreted 
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by astrocytes [96,97]. Besides laminin, other key components of the BMs are network forming 
collagen type IV (Figure 5a), fibronectin, nidogen and heparan sulfate proteoglycans (e.g., agrin and 
perlecan). All these components of the BM undergo spontaneous self-assembly into higher order 
networks. Nidogen and perlecan spontaneously bind to each other, and then form a bridge between 
laminin and collagen IV, where nidogen is connected to the Ƴ chain of laminin (Figure 5c). 
Importantly, cells actively support the self-assembly of BM components through mediation of signals 
to and from the cell cytoskeleton with the help of cell-surface receptors [98,99]. This complex self-
assembly process is pictorially represented through simplified sketches shown in Figure 5d. 
Many of these extracellular matrix (ECM) components are natural ligands for receptors 
expressed by the abluminal membranes of the capillary ECs, as well as astrocytes and pericytes.
These receptors are mostly different subclasses of integrins such as α1β1, α6β1, α6β4, α3β1, αvβ1, 
αvβ3, α5β1 and α4β1 and dystroglycans [100]. Besides matrix receptors, the ECs also express 
important GF receptors on their surface for binding soluble factors released from pericytes and 
astrocytes. The BMs are endowed with the ability to entrap these soluble factors released from 
cellular components of the NVU. These can include TGF-β and Shh, secreted by pericytes and 
astrocytes, Ang-1 released from pericytes and Wnt secreted by astrocytes. The binding of these GFs, 
as well as ECM components, to their corresponding receptors expressed by ECs can induce 
important cell signalling events leading to upregulation of important TJ proteins resulting in barrier 
tightness [101]. For example, agrin receptors are expressed by ECs and the binding of agrin to its 
receptor can upregulate the expression of TJ proteins Claudin-5 and occludin. In glioblastoma, when 
agrin is lacking, Claudin-5 and occludin expressions are also supressed [102]. Depletion of agrin could 
also cause depolarisation of astrocytic end-feet primarily by perturbing the distribution of aquaporin 
4 (AQP4) [103]. Perlecan is another major functional unit of the BM because it interacts and grounds 
several GFs including vascular endothelial growth factor (VEGF), PDGF and TGF-β in the ECM [104]. 
During stroke, perlecan undergoes proteolytic cleavage and some of these cleaved products, 
particularly the protein fraction containing C-terminal domain V (DV), can be beneficial for restoring 
motor function and reducing glial scars [105]. Laminins also play an important part in promoting BBB 
tightness. Laminins bind to integrin subtypes containing β1 chains and this binding mediates EC 
attachment to the BM promoting Claudin-5 localisation at the TJ. When β1 integrins are blocked, the 
expression of Claudin-5 gets suppressed resulting in the increased paracellular permeability of the 
endothelial barrier [106]. Interestingly, a recent report has claimed that laminin-111 of the glia 
limitans maintains BBB integrity by preventing the differentiation of pericytes from the resting stage 
(stable) to the contractile or BBB-disrupting stage [107]. It has been demonstrated that pericytes 
release Ang-1, which can upregulate the gene encoding TJ protein occludin by activating the Tie-2-
mediated signalling pathway [81]. In recent years, Wnt/β-catenin-mediated signalling has been 
recognised as the major player in inducing BBB characteristics in the developing brain, as well as 
maintaining the barrier phenotype in adulthood [108]. The astrocytes release Wnt ligands, which are 
then trapped by the BM matrix as they undergo post-translational modification [109]. The inhibitory 
factors of Wnt render them inactive whereas TGF-β signalling triggers their activation by reducing 
the concentration of Wnt inhibitors thus releasing Wnts from the matrix [110]. The Wnt ligands bind 
to their target receptors (Frizzled 4 and LRP/6) expressed by the ECs and the binding interaction 
initiates the β catenin signalling pathway, resulting in the transcription of genes encoding TJ proteins 
[17]. Moreover, injection of soluble inhibitors of Wnt in vivo has been found to generate vascular 
defects and breakdown of the BBB [111]. This evidence strongly suggests that Wnts are involved in 
the regulation and maintenance of normal BBB functions. Another important morphogen secreted 
by astrocytes and pericytes on the BM matrix is Shh, which can bind to Patched-1/[s6]Smoothened[s7]
receptors on the endothelial membranes and can modulate the expression of TJ proteins by 
activating specific transcription factors such as Gli-1 [112]. The complex bidirectional crosstalk 
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between the BMs and cellular components of the NVU using soluble factors as the mediators is 
depicted in Figure 6. 
Cell-support materials can regulate NVU functions
Because the binding of the natural constituents of the BMs to the matrix receptors on the surface of 
the endothelial membranes promotes cell adhesion, growth, proliferation and migration, the BM 
components, in particular collagen, laminin and fibronectin, are often used as scaffold materials to 
mimic the function of these proteins in in vitro BBB cultures. Tilling et al. first systematically 
investigated the influence of cell-support materials in regulating TEER in vitro using porcine brain 
endothelial cell monolayers. Cells seeded on type IV collagen, fibronectin, laminin and a combination 
of all three proteins in the ratio of 1:1:1 showed elevated TEERs in comparison with cells cultured on 
rat tail collagen type I [113]. Interestingly, type I collagen is not naturally present in the brain BM. In 
another study, RBE4.B cell lines grown on collagen type I coated matrix failed to show mRNA 
expression coding for occludin, whereas collagen type IV or laminin coated substratum were able to 
trigger occludin mRNA expression [114]. These results indicate that cell culture scaffold materials 
can influence the tight barrier formation. By contrast, in the study reported by Vandenhaute et al.
three different coatings (Matrigel®, laminin and PDL) were used in the following combinations: (i) 
Matrigel® on top face; (ii) laminin + Matrigel® on top face of filter membrane; (iii) PDL on bottom 
face of filter and Matrigel® on top; and (iv) PDL at bottom, layer of laminin and Matrigel® on top face. 
Surprisingly, this study failed to demonstrate any significant effect on membrane permeability of LY, 
but showed EC monolayer invasion and growth of a second monolayer at the filter bottom face filter 
and the expression of ZO-1 [28]. Irrespective of the nature of coating used, the double layer of 
endothelial growth was prevented by culturing solely ECs with a dry bottom for one week followed 
by seeding of pericytes to achieve co-culture conditions. From this study, the authors concluded that 
the mechanism of EC invasion was physical and not biochemically controlled by coating of the insert. 
Thus, the nature of the cell culture coating might not influence the migratory aptitude of ECs in vitro. 
However, to date, the precise mechanism of interaction between BBB BM and the NVU components 
is still not clear and more-elaborate studies in this avenue remain to be done. In a study by Hartman 
et al., porcine BCECs were allowed to grow on an ECM deposited by astrocytes and pericytes. The 
TEER was then compared with cells grown on matrices produced from brain and non-brain ECs and it
was significantly higher for ECs cultured on the glial-derived ECM. This proves that the components 
of the astroglial BMs are particularly essential for controlling BBB tightness [115]. Recently, an 
elegant study has shown that BM proteins can regulate the astrocytic phenotypic morphology in in 
vitro cultures. When human fetal-derived astrocytes were cultured on different cell culture coating 
materials – Matrigel®, fibronectin, collagen IV and collagen I – the best astrocyte-like morphology 
involving protrusions and branchings was displayed on Matrigel®-coated surfaces [116]. In a recent 
follow-up study, this group fabricated a newly designed matrix comprising hyaluronic acid 
polysaccharide, Matrigel® and collagen. The human fetal-derived astrocytes grown on this matrix 
not only developed star-shaped morphology with radial processes but also maintained normal 
expression levels of glial fibrillary acidic protein (GFAP) [117]. Surprisingly, before this study, the 
astrocyte phenotype was hardly described in most co-culture BBB models with brain ECs. In fact, rat 
astrocytes frequently co-cultured with BMECs were reported to adopt a rounded morphology with 
short processes and also showed elevated levels of GFAP [118]. These are interesting results 
unambiguously pointing towards the fact that the composition of the cell culture matrix can guide 
the differentiation of cells into their true phenotype in in vitro cell culture models. 
New outlook for in vitro BBB modelling 
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Even though during the past decade a tremendous amount of research effort and resource has been 
invested in developing new cell culture models of the BBB with strong barrier characteristics that 
persist in vivo, a model that can be recognised as the gold standard for predictable high-throughput 
screening application has not yet been reported. A major area of concern that remains consistent in 
the majority of these BBB in vitro cell culture models is the lack of reproducibility in experimental 
outcomes. Related to this concern, a significant area of development that has been mostly 
overlooked is the introduction of novel cell culture platforms for generating BBB models. The 
standard coating materials that have been applied on filter supports for seeding BECs reported to 
date are rat tail collagen type I, collagen type IV, fibronectin, gelatin, mouse laminin, Matrigel® and 
PDL. An exhaustive list of cell culture materials used for establishing in vitro BBB models is 
summarised and presented in a tabular form by Bicker et al. [51]. Interestingly, PDL is not a natural 
component of the BM and gelatin is denatured collagen. If we recollect the information presented 
by Hartman et al. [115], then these materials might not be considered as desirable for imparting 
strong barrier characteristics. Also, collagen type I has been most widely used as a cell support 
material in BBB models. Although collagen type I can provide structural support to the cells, it has 
fibrillar architecture contrary to natural BM collagen type IV, which forms a higher order polygonal 
network structure (Figure 5a). Hence, the structural characteristics of cells growing on membranes 
coated with collagen type I are not even similar with the natural BM of the NVU. An effect of this 
structural dissimilarity in BBB models is reflected by the findings reported by Tilling et al. as 
described earlier [113]. Interestingly, astrocytes cultured on Matrigel® support were able to 
reproduce some of the best phenotypic characteristics and yet Matrigel® represents the BM 
extracted from mouse tumour, and hence has the potential to introduce diseases. Similarly, collagen 
type IV is usually obtained from animal species, such as bovine, and chances are it can elicit 
immunogenic responses. Moreover, because these natural ECM components are isolated from 
different animal sources they are heterogeneous or do not have a fixed composition and this batch-
to-batch variation in their composition could easily affect the overall reproducibility of experimental 
results. Consequently, the lack of reproducibility in data obtained from in vitro cell culture models is 
still the major hurdle that has prevented their customisation as robust in vitro models for routine 
drug screening. Additionally, large proteins, such as collagen and fibronectin, are difficult to modify 
because they tend to denature and often lose their mechanical properties when subjected to 
chemical modification. 
An alternative strategy would be to engineer novel cell culture platforms from synthetic 
building blocks that will mimic the structure and functions of the BBB BMs and still be nontoxic. 
Natural or synthetic polymers, peptide amphiphiles (PAs) or even polymer peptide conjugates can be 
considered for this type of design purpose. However, the most challenging part in constructing an 
artificial BM is to mimic the hierarchical organisation of the membrane architecture, while at the 
same time the membrane should be bioactive so that the cells can respond to cues provided by the 
membrane. In principle, we can readily obtain nanofibres by the self-assembly of rationally designed 
PAs and, depending on the in-built peptide sequence, the nanofibres could even respond to cellular 
cues; however, in most cases, the self-assembly is more likely to produce hydrogels rather than 
stable membranes [119,120]. Conversely, a recent paper has documented a synthetic self-assembly 
approach for the generation of mechanically stable membranes from peptide–polymer mixtures. 
The authors used electrospinning processing to induce fibre formation and, because the membranes 
contain bioactive peptide sequences, they supported the adhesion, growth and long-term culture of 
primary renal epithelial cells displaying strong barrier properties [121]. Recently, our group has 
reported the design of self-assembled bioactive robust membranes by simple mixing of hyaluronic[s8]
acid with β-sheet fibril forming PA incorporating a matrix metalloproteinase (MMP)-1-sensitive 
sequence. The membranes supported the adhesion and growth of dermal fibroblasts and underwent 
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slow degradation when treated with recombinant MMP-1 in vitro [122]. Therefore, implementing a 
self-assembly strategy for forming higher-order BM network structures will be a promising approach 
for generating artificial BMs of the BBB. Integration of small peptide epitopes such as cell adhesion 
sequence or specific GF-binding sequences (e.g., TGF-β) into these self-assembled membranes can 
render the scaffold bioactive and attractive for GF binding. Consequently, now the scaffold can 
mediate cell adhesion and regulate cell signalling events through controlled local release of bound 
GFs. Because the cellular components of the BBB communicate with each other through release of 
soluble factors, which are captured and released by the BMs, the incorporation of this feature into 
an artificial BM construct will induce barrier tightness by regulating the expression of TJ proteins. 
Moreover, the composition of a synthetic BM is fixed, maximising the reproducibility of 
experimental outcomes. Thus, an in vitro BBB model recreated on an engineered artificial synthetic 
membrane support can be considered as more predictable than when natural protein components 
of the ECM matrix are used as scaffold materials for cell growth. Depending on how well the cells 
communicate with these artificial membranes, the in vitro BBB model can be fine-tuned for 
customisation for routine use in high-throughput studies in drug discovery and development 
research.
Lastly, the BBB microvasculature is composed of arteries, venules and capillaries and a 
certain level of heterogeneity is expected for ECs isolated from these sources in terms of 
physiological properties. For example, ECs extracted from capillaries are comparatively less 
permeable than ECs from arterioles and venules [123,124]. Considering this viewpoint, we can 
assume that a level of overall heterogeneity in the composition, morphology and functions of the 
BM exist depending on their anatomical localisation in the microvasculature. Although this variability 
can impose a formidable challenge when considering the design of a new BM, on the brighter side, 
because the BM will be synthetically constructed, one can manipulate the choice of bioactive 
materials taking into account the composition at different subanatomical sites.
Concluding remarks
In vitro BBB models are indispensable screening tools for determination of drug delivery into the 
brain. In recent decades, intense research has produced some impressive in vitro cell-based model 
systems, some novel, whereas others improved variations of pre-existing models. Each model 
system comes with its own ingenious design, applications and limitations (Table 2). However, a 
common fundamental feature that is ubiquitous in these models is the lack of better cell-support 
materials that can mimic more accurately the organised structure and functions of the BBB 
extracellular environment. Thus, we foresee a new area of advancement through construction of 
artificial bioactive membranes that can emulate the performance of the BBB BM. Moreover, the 
core value of this approach lies in the fact that already established and potential in vitro models can 
be regenerated on these new cell culture platforms with a promise of gaining higher predictability 
and a possible pathway leading towards customisation in pharmaceutical research.
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Figure legends
Figure 1. [s9]Schematic[s10] representation of the neurovascular unit (NVU) at the site of the brain 
capillaries: the cerebral blood capillaries in the brain are lined by a continuous layer of endothelial 
cells (ECs) surrounded by the endothelial basement membrane (BM), in which the brain pericytes 
are embedded. The astrocytic end-feet surround the ECs but are not in direct contact with them;
instead the BM separates the astrocyte foot processes from the ECs. The astrocytes also maintain 
close association with the neurons. Microglia are the immune cells of the central nervous system 
(CNS). Occasionally, there are gaps or discontinuities in the astrocytic end-feet coverage where 
neurons and microglia can innervate the BM. Note: the capillary lumen and walls, and the BM, are 
relatively scaled, but other components of the NVU are indicated, but not scaled. Adapted, with 
permission[s11], from [1,150].
Figure 2. Transwell culture system typically used in in vitro blood–brain barrier (BBB) models and 
measurement of trans-endothelial electrical resistance (TEER) employing traditional chopstick 
electrodes of the voltohmmeter type (EVOM). Transwell plate with a total of six (ai), 12 (aii) or 24 
(aiii) wells containing a porous filter insert (aiv) which divides the transwell into upper apical or 
blood compartment and lower basolateral or brain compartment. (bi) Measurement of TEER for a 
porous semipermeable membrane insert (control); (bii) a uniform layer of brain endothelial cells 
(BECs) are seeded on the top of the filter membrane coated with an extracellular matrix (ECM)-
derived protein (e.g., collagen I, collagen IV, laminin, fibronectin, gelatin from rat or bovine), 
Matrigel® or Matrigel™ [s12][a solubilised basement membrane (BM) preparation extracted from the 
Engelbreth-Holm-Swarm mouse sarcoma, a tumour rich in ECM proteins such as laminin, collagen IV, 
heparin sulfate proteoglycans, nidogen and a number of growth factors (GFs)], matrices deposited 
by cultured astrocytes or pericytes or synthetic poly-D-lysine (PDL). TEER of confluent endothelial 
monolayer is recorded by placing two electrodes, one on each side of the transwell compartments as 
shown. (ci) Measurement of TEER with astrocytes seeded at the bottom face of filter (control); (cii) 
TEER measurement of a typical contact co-culture system. Adapted, with permission, from [3,6].
[s13]Figure 3. Mono-, co- and tri-cultivation models of the blood–brain barrier (BBB). (a) Mono-
culture model: the endothelial monolayers are cultured on transwell membrane insert. (bi) 
Endothelial–glial co-culture model in non-contact configuration. Astrocytes are cultured on the 
bottom of the transwell, whereas endothelial monolayer is cultured on top of the filter membrane; 
(bii) endothelial–glial co- ulture in contact orientation. The astrocytes are seeded on the bottom of 
the filter membrane so that they are in close proximity with the endothelial cells (ECs) cultured on 
top of the filter; (biii) co-culture of pericytes at the bottom of well; (biv) contact co-culture model 
with pericytes. (ci) Tri-culture model involving ECs, astrocytes and pericytes with pericytes cultured
on opposite side of filter; (cii) another format of tri-cultivation model. Here astrocytes are in contact 
orientation and pericytes cultured at the bottom of the well; (ciii) pericytes and ECs are in very close 
contact and astrocytes cultured at the bottom. This configuration very closely mimics the in vivo
anatomical organisation of the neurovascular unit; (civ) non-contact format of tri-culture model 
involving ECs, astrocytes and pericytes. Adapted, with permission[s14], from [12,55,58].
Figure 4. [s15]Schematic representation of dynamic in vitro blood–brain barrier (BBB) model. The 
endothelial cells (ECs) are cultured inside the fibronectin-coated surface of hollow fibres made up of 
polypropylene. This system allows co-culture, because astrocytes can be cultured on the outer 
surface of the hollow fibres. A single hollow fibre is highlighted in yellow. A bundle of these hollow 
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fibres is then packed inside a sealed chamber. The cell-culture medium is pumped through the 
chamber by a pump with adjustable speed control. The pulsatile flow of the cell-culture medium 
mimics the flow environment that persists in vivo, and helps to generate the sheer stress. Adapted, 
with permission, from [s16][11].
Figure 5. [s17]Supramolecular assembly of basement membrane (BM) and its major components: 
collagen IV, laminin, nidogen, agrin and perlecan. (a) Collagen IV network formation: an assembled 
protomer contains a triple helical domain flanked by a short 7S domain at the N-terminal and a 
noncollagenous globular trimeric domain (NC1) at the C-terminal. The NC1 domains of two 
protomers interact to form NC1 hexamers (dimer). Next, four protomers interact at the 7S domain 
to form tetramers (ordered lattice structure), adapted, with permission[s18], from [151]. (b) Laminin 
network formation through polymerisation: cruciform structure of laminin containing α, β and γ 
chains. Typically, α-chain of laminin contains a domain that binds other extracellular matrix (ECM)
proteins, an α-helical region and an integrin-binding domain. Primary interactions lead to a trimer 
formation, by the binding of three different domains, followed by polymerisation, adapted, with 
[s19]permission, from [152]. (c) Complex molecular interactions among different components of the 
BM directing the self-assembly process: nidogen and perlecan mediates laminin-collagen IV binding 
whereas agrin binds to laminin, adapted, with [s20]permission, from [153,154]. (d) Agrin and the 
laminin network are anchored to the cell surface by interactions with integrins, α-dystroglycan and 
sulphated glycolipids/sulfatides. Adapted, wit[s21]h permission, from [154,155]
Figure 6. Involvement of the basement membrane (BM) in complex bidirectional cross-talk with 
other components of the neurovascular unit (NVU). Astrocytes and pericytes release cell secretomes 
[e.g., transforming growth factor (TGF)-β, Shh, Ang-1, Wnt] that get entrapped on the BM. The cell 
membrane of the endothelial cells (ECs) expresses a number of receptors for these released factors 
to bind and stimulate important cell signalling events that could lead to the upregulation of the tight 
junction (TJ) protein expressions. The BM components can also bind to their corresponding 
receptors expressed by the EC membranes (e.g., laminin binding to β1 integrins and agrin binding to 
agrin receptors). Adapted, with permission[s22], from [101]. 
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Table 1. Commonly used in vitro BBB models for studying uptake and delivery of nanoformulations into the brain; different types of nanoparticle are 
acting as carriers for loaded cargoes, which can include chemotherapeutics, diagnostics, fluorescent dyes serving as model drugs, genes, proteins and 
antibodies 
 
Loaded therapeutics or 
cargoes 
Type of 
nanocarrier 
Ligand used for 
surface 
modification   
Nature of 
BECs 
Co-culture 
cell type  
Observations Refs 
Carmustine 
(chemotherapeutics) 
Solid lipid NP 83-14 mAb; 
targets insulin 
receptor 
Primary 
human 
Human 
astroglia 
Enhanced permeability and cellular uptake of 
carmustine via insulin receptor mediated 
endocytosis 
[125] 
Saquinavir 
(antiretroviral)  
Solid lipid NP 83-14 mAb; 
targets insulin 
receptor 
Primary 
human 
Human 
astroglia 
BBB permeability increases with increasing 
concentrations of mAb. The enhanced permeability 
is the result of recognition and stimulation of cell 
surface insulin receptors by mAb 
[126] 
BDNF Magnetic iron 
oxide NP 
None Primary 
human 
Human 
astroglia 
Nearly 73% of BDNF bound magnetically guided NP 
were able to cross the BBB 
[127] 
Albumin 
(model for protein) 
Maltodextran Cationic charge 
lipid coating on 
the surface 
Primary 
bovine 
Rat glia Increased permeability of albumin  [128] 
6-Coumarin 
(fluorescent probe) 
PEG-PLA NP 
 
Cationic BSA Primary 
rat  
Rat 
astrocytes 
Significant accumulation of cationic NPs in the 
lateral, third and the peri ventricles 
[129] 
DNA (gene delivery) DGL-PEG NP  Leptin derived 
30 amino acid 
peptide (Leptin 
30) 
 b.End3 
cell line, 
mouse 
None The polymer was effectively transported across the 
BBB  
[130] 
Dalargin  
an endorphin; opioid 
analgesic 
PBCA NP Polysorbate-80 
coating 
Primary 
bovine 
Rat glia Not given [131] 
Zidovudine (retroviral) PBCA NP CRM197 
(targets 
diphtheria toxin 
Primary 
human 
Human 
astroglia 
Enhanced permeability of zidovudine with 
increasing CRM-197 concentration in the 
formulation 
[132] 
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receptor) 
TIMP-I (example of 
protein delivery) 
PLGA NP 
 
Polysorbate-80 
coating 
Primary 
rat and 
RBE4 cell 
line, rat 
None About 11.21 ±1.35% of TIMP-I was able to cross the 
EC monolayer whereas only TIMP-1 and TIMP-1-
PLGA (without polysorbate) were not able to 
penetrate the cultured monolayer  
[133] 
D4T, delavirdine and 
saquinavir 
(antiretroviral drugs) 
MMSM NP  Bradykinin type 
II receptor 
agonist (RMP-7) 
Primary 
human 
Human 
astroglia 
RMP-7 enhanced the paracellular and transcellular 
permeability of the three drugs across the EC 
monolayer and the order of increase of Pe 
(D4T>saquinavir>delavirdine) 
[134] 
Loperamide 
(analgesic) 
PLGA-PEG-PLGA 
NP 
 
Polxamer 188 or 
polysorbate 80 
coating 
RBE4 cell 
line, rat 
Rat C6 BBB permeability of drug encapsulated NP was 
13.7-fold higher than free drug solution 
[135] 
Docetaxel 
(anticancer activity) 
PEG-PCL NP 
 
AS1411 
aptamer for 
glioma targeting 
and TGN 
peptide for BBB 
targeting 
b.End3 
cell line, 
mouse 
Rat C6 Demonstrated improved penetration power 
through b.End3 and C6 spheroids with significant 
decrease in growth of tumour spheroid 
[136] 
Flubiprofen 
(therapeutics for 
Alzheimer’s disease) 
PLA NP 
 
None b.End3, 
mouse 
None PLA-flubiprofen was able to penetrate the BBB and 
the transported flubiprofen could modulate the 
activity of enzyme Ƴ-secretase 
[137] 
Oximes (muscarinic 
receptor antagonist) 
PEG-HSA NP  ApoE (targets 
LDL receptors 
on brain ECs) 
Primary 
porcine  
None Higher concentration of Apo-E modified oxime 
bound nanoparticle was detected in basolateral 
compartment compared with controls 
[138] 
siRNA for MMP-9 gene 
silencing 
Quantum dots None Primary 
human 
Human 
astroglia 
Increased uptake and MMP-9 gene silencing 
 
[139] 
IgG (model antibody) Polymersomes 
(synthetic 
vesicles formed 
by amphiphilic 
co-polymers) 
Angiopep-2 and 
rabies virus 
glycoprotein 
peptide 
receptor target: 
LRP-1 
bEnd.3, 
mouse 
Mouse 
pericyte or 
C8-D1A 
mouse 
astrocytic 
cell line 
Not given  [140] 
NGF (model for GF Liposomes RMP-7; ligand Primary None Pe of nanoparticle formulation containing NGF  = [141] 
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delivery) for B2 receptor 
on BMECs 
mouse  2.58 ±0.11 × 106 cm s-1 (Pe for free NGF = 1.85 
±0.04 × 106 cm·s-1) 
Curcumin derivative 
(natural component of 
spices such as turmeric, 
believed to possess 
anti-inflammatory 
properties) 
Nanoliposome ApoE-derived 
peptide 
RBE4 cell 
line, rat 
None The Pe value of curcumin was enhanced with 
increasing loading density of ApoE peptide 
[142] 
99mTc-BMEDA serving as 
diagnostic 
PEGylated 
liposomes  
Lactoferrin b.End3, 
mouse 
None Enhanced uptake by the cells; amount uptake 
remained unaffected by incubation time 
[143] 
Daunorubicin 
(anticancer activity) 
Sugar and 
transferrin 
coated dual 
targeting 
liposome 
Transferrin Primary 
murine 
Murine C6 
glioma cell 
line 
The transport ratio across the EC monolayer of 
daunorubicin in liposomal formulation was 24.9% 
compared with 3.1% of free drug  
[144] 
Paclitaxel 
(anticancer activity) 
Third 
generation G3 
PAMAM 
dendrimer 
None Primary 
porcine 
None The dendrimer–drug conjugates exhibited 
increased Papp in either directions across the 
transwell culture of EC compared with unmodified 
dendrimer and free drug 
[145] 
7 Doxorubicin 
(anticancer activity) 
4th generation 
PAMAM 
dendrimer 
conjugated with 
transferrin and 
tamoxifen  
pH sensitive 
transferrin 
tamoxifen 
acting as P-gp 
inhibitor 
Primary 
murine 
Murine C6 
glioma 
The drug formulation showed a transport ratio of 
6% in 3 h and the carrier was internalised by C6 
glioma cells after transport across the cultured EC 
monolayer  
[146] 
Doxorubicin 
(anticancer activity) 
Stearic acid 
grafted chitosan 
micelle 
None b.End3, 
mouse 
Mouse C6 
glioma 
Enhanced uptake of the micelles by b.End3 cells. 
Cytoxicity of doxorubicin micelle towards C6 
glioma cells was 2.664 ±0.036 µg/ml verses 0.181 
±0.066 µg/ml of free drug 
[147] 
Kynurenic acid 
(endogenous glutamate 
antagonist) 
Triton X 100 
and Lutensol® 
AP 20 micelles 
None Primary 
rat 
Rat 
astrocytes 
BBB permeability was significantly higher for 
encapsulated kynurenic acid compared to the free 
acid 
[148]  
BSA-FITC (fluorescent Bolaamphiphilic Acetylcholine b.End3, None Higher cellular uptake of BSA-FITC encapsulated [149] 
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Abbreviations: ApoE, apoliprotein E; BBB, blood–brain barrier; BDNF, brain-derived neurotrophic factor; BEC, brain endothelial cells; BMEDA, N,N-bis(2-mercaptoethyl-N
ʹ
,N
ʹ
diethylethylene 
diamine); CRM-197, ligand for diphtheria toxin receptor; DGL, dendrigraft poly-L-lysine; FITC, fluorescein isothiocyanate; HAS, human serum albumin; IgG, immunoglobulin G; LDL, low-density 
lipoprotein; mAb, monoclonal antibody; MMSM, methyl-methacrylate-sulphopropyl-methaacrylate; MMP-9, matrix metalloproteinase-9; NGF, nerve growth factor; NP, nanoparticle; 
PAMAM, polyamidoamine; Papp, apparent permeability coefficient; PBCA, poly-butylcyanoacrylate; PEG, polyethylene glycol; PLA, poly-lactic acid; PLGA, poly-lactic-co-glycolic acid; PLA, poly-
L-lactide; RMP-7, receptor-mediated permeabiliser-7; TIMP-I, tissue inhibitor of matrix metalloproteinase-I; cereport, a bradykinin analogue. 
 
 
labelled protein for 
detection) 
nano-sized 
cationic vesicles 
surface bound mouse bolaamphiphiles compared with free BSA-FITC at 
37°C 
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Table 2. Summary of advantages and limitations of in vitro cell-based BBB models 
 
In vitro BBB 
models 
 Pros Cons 
Transwell monoculture 
model 
2D culture of BEC 
monolayers under static 
conditions (Figure 3a) 
 Simple and cost-effective 
 Can be cultured with astrocyte-
conditioned media 
 Highly convenient for high-
throughput screens 
 
 Fast de-differentiation of 
endothelial monolayers leading to 
loss in phenotype and functions 
 Influence of neighbouring NVU 
components (astrocytes, pericytes 
and neurons) on endothelial cell 
differentiation is absent 
 Inadequate paracellular barrier 
tightness 
Transwell co-culture 
model (static model) 
2D culture of EC 
monolayers in presence 
of either astrocytes or 
pericytes (Figure 3). 
Two types of 
orientation are possible: 
(i) contact (back-to-
back) with astrocytes or 
pericytes (Figure 
3bii,3biv) and (ii) non-
contact (non back-to-
back) (Figure 3bi,3biii) 
 Enhanced barrier tightness and 
less EC de-differentiation in 
comparison with monoculture 
models 
 The influence of astrocytes or 
pericytes on barrier functions 
can be evaluated 
 More complex than monoculture 
models 
 Variation in research results 
 Astrocyte phenotypic morphology 
is often not described or 
astrocytes might even adopt a 
rounded morphology instead of 
usual star-shaped with 
protrusions and branches 
 The thickness of the 
semipermeable membrane insert 
does not accurately reflect the 
true thickness of the BM in vivo, 
which is comparatively much 
thinner 
Transwell tri-culture 
model (static model) 
Culture of ECs in 
presence of astrocytes 
and pericytes or 
astrocytes and neurons. 
Contact and non-
contact formats are 
possible (Figs 3ci—3civ) 
 Resembles more closely the 
actual in vivo brain anatomy 
 Some of the reported models 
show considerable improvement 
in BBB phenotype and 
paracellular permeability than 
co-culture models 
 Complex to set up 
 Lack of reproducibility and 
variation in data 
 Astrocyte morphology not 
described categorically 
 Inclusion of pericytes in some 
models did not improve barrier 
properties 
 Access to three different cell types 
is required 
Static tri-culture models 
using EC derived from 
stem cells (pluripotent 
or hematopoietic) 
 Excellent source for establishing 
human in vitro BBB models 
 Scalable; can be produced at 
large scales 
 High TEER more close to in vivo 
parameter using pluripotent 
human stem cells 
 Differentiation process is complex 
 Decrease in TEER within short 
time intervals 
 
Dynamic in vitro BBB 
models (Figure 4) 
 
 Considers the effect of in vivo 
sheer stress  
 Improved TEER compared with 
static models 
 Require higher cell numbers 
 Maintenance of high flow rate 
owing to large volume of the 
hollow tubes 
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Abbreviations: BBB, blood–brain barrier;  
 
 Design allows co-culture with 
astrocytes 
 
 Technically challenging 
 Incompatible with high-
throughput screening 
Microfluidic models  Requires less cell number 
 Can consider the effect of sheer 
stress 
 Improvement in paracellular 
barrier functions 
 Visualisation of cells is possible 
 The exact geometry of the BMEC 
phenotype is not very well 
defined 
 TEER values are moderate 
 
Hypothetical model 
using bioactive 
synthetic BM  
 Considers the realistic effect of 
brain microenvironment 
 Can mimic the supramolecular 
architecture of the natural BM 
 Ability to regulate cell 
phenotypes by providing 
biochemical cues within the 
synthetic BM 
 Fixed composition leading to 
improvement in reproducibility 
of results 
 Possibility of customisation for 
performing mechanistic studies 
 Can be endowed with the ability 
to entrap and release soluble 
factors in a controlled manner 
 Ability to re-establish any of the 
models on this new cell culture 
platform 
 Control thickness of synthetic 
BM  
 Challenges are there to design 
and fabricate artificial membranes 
 Requires knowledge on molecular 
engineering of biomaterials 
 Has to support the culture of cells 
of the NVU 
 Will require rigorous optimisation 
owing to scarcity of previous 
literature reports 
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